Literature DB >> 25037918

Discovery libraries targeting the major enzyme classes: the serine hydrolases.

Katerina Otrubova1, Venkat Srinivasan1, Dale L Boger2.   

Abstract

Two libraries of modestly reactive ureas containing either electron-deficient acyl anilines or acyl pyrazoles were prepared and are reported as screening libraries for candidate serine hydrolase inhibitors. Within each library is a small but powerful subset of compounds that serve as a chemotype fragment screening library capable of subsequent structural diversification. Elaboration of the pyrazole-based ureas provided remarkably potent irreversible inhibitors of fatty acid amide hydrolase (FAAH, apparent Ki=100-200 pM) complementary to those previously disclosed enlisting electron-deficient aniline-based ureas.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Enzyme inhibitors; Fatty acid amide hydrolase; Screening library; Serine hydrolase inhibitors

Mesh:

Substances:

Year:  2014        PMID: 25037918      PMCID: PMC4130767          DOI: 10.1016/j.bmcl.2014.06.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  90 in total

1.  Activity-based protein profiling: the serine hydrolases.

Authors:  Y Liu; M P Patricelli; B F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 2.  Mechanism-based profiling of enzyme families.

Authors:  Michael J Evans; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2006-08       Impact factor: 60.622

3.  Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism.

Authors:  M P Patricelli; B F Cravatt
Journal:  Biochemistry       Date:  1999-10-26       Impact factor: 3.162

4.  Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

Authors:  Douglas S Johnson; Cory Stiff; Scott E Lazerwith; Suzanne R Kesten; Lorraine K Fay; Mark Morris; David Beidler; Marya B Liimatta; Sarah E Smith; David T Dudley; Nalini Sadagopan; Shobha N Bhattachar; Stephen J Kesten; Tyzoon K Nomanbhoy; Benjamin F Cravatt; Kay Ahn
Journal:  ACS Med Chem Lett       Date:  2011-02-10       Impact factor: 4.345

5.  Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.

Authors:  Marvin J Meyers; Scott A Long; Matthew J Pelc; Jane L Wang; Scott J Bowen; Barbara A Schweitzer; Mark V Wilcox; Joseph McDonald; Sarah E Smith; Susan Foltin; Jeanne Rumsey; Young-Sun Yang; Mark C Walker; Satwik Kamtekar; David Beidler; Atli Thorarensen
Journal:  Bioorg Med Chem Lett       Date:  2011-08-19       Impact factor: 2.823

6.  Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues.

Authors:  Katerina Otrubova; Monica Brown; Michael S McCormick; Gye W Han; Scott T O'Neal; Benjamin F Cravatt; Raymond C Stevens; Aron H Lichtman; Dale L Boger
Journal:  J Am Chem Soc       Date:  2013-04-12       Impact factor: 15.419

7.  An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase.

Authors:  M P Patricelli; J E Patterson; D L Boger; B F Cravatt
Journal:  Bioorg Med Chem Lett       Date:  1998-03-17       Impact factor: 2.823

8.  CSI-FID: high throughput label-free detection of DNA binding molecules.

Authors:  Karl E Hauschild; James S Stover; Dale L Boger; Aseem Z Ansari
Journal:  Bioorg Med Chem Lett       Date:  2009-05-03       Impact factor: 2.823

9.  Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.

Authors:  Christophe Hardouin; Michael J Kelso; F Anthony Romero; Thomas J Rayl; Donmienne Leung; Inkyu Hwang; Benjamin F Cravatt; Dale L Boger
Journal:  J Med Chem       Date:  2007-06-09       Impact factor: 7.446

10.  Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.

Authors:  Jin Shi; James S Stover; Landon R Whitby; Peter K Vogt; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2009-09-17       Impact factor: 2.823

View more
  6 in total

1.  Design of Benzoxathiazin-3-one 1,1-Dioxides as a New Class of Irreversible Serine Hydrolase Inhibitors: Discovery of a Uniquely Selective PNPLA4 Inhibitor.

Authors:  Anne F Kornahrens; Armand B Cognetta; Daniel M Brody; Megan L Matthews; Benjamin F Cravatt; Dale L Boger
Journal:  J Am Chem Soc       Date:  2017-05-12       Impact factor: 15.419

2.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

3.  N-Acyl pyrazoles: Effective and tunable inhibitors of serine hydrolases.

Authors:  Katerina Otrubova; Shreyosree Chatterjee; Srijana Ghimire; Benjamin F Cravatt; Dale L Boger
Journal:  Bioorg Med Chem       Date:  2019-03-11       Impact factor: 3.641

4.  Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency.

Authors:  Francesca Galvani; Laura Scalvini; Silvia Rivara; Alessio Lodola; Marco Mor
Journal:  J Chem Inf Model       Date:  2022-05-17       Impact factor: 6.162

5.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

6.  Comparative analysis of the human serine hydrolase OVCA2 to the model serine hydrolase homolog FSH1 from S. cerevisiae.

Authors:  Jessica S Bun; Michael D Slack; Daniel E Schemenauer; R Jeremy Johnson
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.